/
•
•
Context is everything.
Detailed stories on technology startups, business and economic current affairs.
Detailed stories on technology startups, business and economic current affairs.
The Hyderabad-based generics maker has seen its stock scale all-time highs and lows in quick succession. With big plans in place and regulatory heat easing, its roller-coaster days may be over.
To borrow from Winston Churchill, Aurobindo Pharma is a riddle, wrapped in a mystery, inside an enigma.
Back in August 2020, the Hyderabad-based company’s stock hit a 10-year high after it dethroned Sun Pharma as the top pharmaceuticals supplier to the lucrative US market. The 2020-21 fiscal was its best ever in terms of profits—at Rs 5,344 crore. We wrote about it here.
At that point, it seemed Aurobindo Pharma couldn’t put a foot wrong. Except it did.
A lot of its good tidings had to do with the US Food and Drug Administration largely clearing it of wrongdoing …
The drugmaker’s reluctance to part with cash may have given it one of the strongest balance sheets in Indian pharma, but investors are increasingly rewarding risk takers.
CEO Rajeev Nannapaneni’s oft-used strategy of mounting patent challenges in the US got the pharma company its latest blockbuster Revlimid. But what after sales fall off a cliff?
A couple of antibiotics that have the potential to change the beleaguered company’s fortunes need a quick infusion of funds to get across the finish line. Can Khorakiwala, the 82-year-old chairman, pull it off?
